MARKET

TVRD

TVRD

Tvardi Therapeutics Inc
NASDAQ
4.300
+0.070
+1.65%
After Hours: 4.300 0 0.00% 16:10 12/31 EST
OPEN
4.200
PREV CLOSE
4.230
HIGH
4.460
LOW
4.120
VOLUME
230.15K
TURNOVER
--
52 WEEK HIGH
43.65
52 WEEK LOW
3.740
MARKET CAP
40.34M
P/E (TTM)
-0.5147
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 12/31/2025 12:06
Weekly Report: what happened at TVRD last week (1222-1226)?
Weekly Report · 12/29/2025 10:25
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Barchart · 12/23/2025 09:18
Weekly Report: what happened at TVRD last week (1215-1219)?
Weekly Report · 12/22/2025 10:25
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Barchart · 12/21/2025 09:11
Tvardi Therapeutics Approves New Severance and Retention Compensation Plan for Executives
Reuters · 12/18/2025 22:21
Weekly Report: what happened at TVRD last week (1208-1212)?
Weekly Report · 12/15/2025 10:32
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Barchart · 12/11/2025 09:15
More
About TVRD
Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Webull offers Tvardi Therapeutics Inc stock information, including NASDAQ: TVRD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVRD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVRD stock methods without spending real money on the virtual paper trading platform.